924416-43-3

Adiponectin expressed by adipocytes exerts antidiabetic effects by binding to adiponectin receptor (AdipoR)1, which activates AMPK pathways, and AdipoR2, which activates PPARα pathways. AdipoRon is an orally active small molecule AdipoR agonist that binds AdipoR1 and AdipoR2 with K_D values of 1.8 and 3.1 μM, respectively. At 50 mg/kg, it acts similarly to adiponectin, activating AMPK and PPARα pathways and reducing insulin resistance and glucose intolerance in wild type mice fed a high-fat diet and in genetically obese db/db mice.

AdipoR agonist that binds to both AdipoR1 and AdipoR2.

AdipoRon is an adiponectin agonist that binds to and activates adiponectin receptors AdipoR1 and AdipoR2, activating AMPK and PPAR-α pathways, and ameliorating insulin resistance and glucose intolerance in mice fed a high-fat diet in a manner similar to adiponectin itself. AdipoRon did not affect body weight, but did increase the expression of genes involved in fatty-acid oxidation, decreased tissue triglyceride content, and prolonged the shortened lifespan of db/db mice.

This orally bioavailable adiponectin receptor agonist (FW = 428.52 g/mol; CAS 924416-43-3; Solubility: 100 mg/mL DMSO; <1 mg/mL H2O), also known as 2- (4-benzoylphenoxy) -N- (1-benzylpiperidin-4-yl) acetamide, stimulates AMPK-mediated phosphorylation and activation of AdipoR1 (Kd = 1.8 μM) and AdipoR1 (Kd = 3.1 μM), which are orientated oppositely to most GPCRs within the membrane (i.e., cytoplasmic N-terminus, extracellular C-terminus), such that they cannot associate with G-proteins. In wild type mice, AdipoRon (orally administered at 50?mg/kg) improves insulin resistance, glucose intolerance, and dyslipidemia by activating AdipoR1–AMPK–PGC-1α pathways in skeletal muscle, while by activating AdipoR2–PPAR-α (Peroxisome Proliferator-Activated Receptor) pathways in the liver.

+4°C

1) Okada-Iwabu?et al. (2013),?A small-molecule AdipoR agonist for type 2 diabetes and short life obesity; Nature 503?493 2) Fairaq?et al.?(2017),?AdipoRon, an adiponectin receptor agonist, attenuates PDGF-induced VSMC proliferation through inhibition of mTOR signaling independent of AMPK: Implications toward suppression of neointimal hyperplasia; Pharmacol. Res.?119?289